- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07616024
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction (INSIGHT-STEMI)
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This study is a prospective, multicenter, randomized controlled, superiority clinical trial. Eligible subjects who meet the inclusion/exclusion criteria will be randomly assigned in a 1:1 ratio to either the IVUS-guided strategy (experimental group) or the conventional coronary angiography-guided strategy (control group). The study plans to enroll at least 2488 subjects, with 1244 subjects in each of the experimental and control groups. Zhongshan Hospital, Fudan University serves as the lead center. A competitive enrollment approach will be adopted, with the number of cases enrolled by the lead center not exceeding 50% of the total sample size.
In the IVUS group, intravascular ultrasound (IVUS) will be used for guidance; the use of high-frequency intravascular ultrasound (resolution ≥ 50 MHz) is encouraged, though not mandatory.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Chenguang Li, Doctor
- Telefonnummer: +8613816767665
- E-post: li.chenguang@zs-hospital.sh.cn
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Zhongshan hospital
-
Hovedetterforsker:
- Junbo Ge, Doctor
-
Ta kontakt med:
- Chenguang Li, Doctor
- Telefonnummer: +8613816767665
- E-post: li.chenguang@zs-hospital.sh.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion criteria
- Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;
- Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);
- Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;
- The IVUS catheter is expected to pass through the target lesion to complete the examination.
Exclusion Criteria
- Patients with cardiogenic shock or severe heart failure (Killip class IV);
- Patients who have previously undergone coronary artery bypass grafting (CABG);
- Patients with coma or disturbance of consciousness;
- Patients who are expected to be intolerant to long-term antiplatelet therapy;
- Pregnant women;
- Life expectancy < 1 year;
- Currently participating in another drug/device clinical trial and not having reached the primary endpoint;
- Poor compliance, expected to be unable to complete follow-up.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: IVUS group
In the experimental group, after the guidewire passes through the lesion, IVUS is used to guide the primary PCI procedure.
|
a catheter equipped with an ultrasound transducer is advanced over a guidewire into the vessel lumen distal to the target coronary lesion.
Then, while slowly withdrawing the catheter, 360-degree cross-sectional images of the vessel are acquired to accurately measure lumen dimensions, assess plaque characteristics, select an appropriately sized stent, and confirm that after stent implantation the stent is fully apposed, well expanded, and free of vascular complications.
Andre navn:
|
|
Annen: CAG group
In the control group, after the guidewire passes through the lesion, coronary angiography is used to guide the primary PCI procedure
|
A catheter is inserted through a peripheral artery (e.g., femoral or radial artery) and advanced to the ostium of the coronary arteries under fluoroscopic guidance.
Once positioned, contrast medium is injected while X-ray images are acquired to visualize the coronary artery lumen and detect any stenoses or occlusions.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary target vessel failure (TVF) rate
Tidsramme: 1 year
|
defined as the composite endpoint of cardiac death, ischemia-driven target vessel revascularization, and target vessel-related myocardial infarction.
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lesion success rate
Tidsramme: Perioperative
|
Lesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
|
Perioperative
|
|
Clinical success rate
Tidsramme: Pre-discharge
|
Lesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
|
Pre-discharge
|
|
Mortality rate
Tidsramme: 1 Year
|
Includes cardiovascular death, non-cardiovascular death, and death of undetermined cause
|
1 Year
|
|
Incidence of myocardial infarction
Tidsramme: 1 year
|
includes periprocedural myocardial infarction as defined by SCAI and spontaneous myocardial infarction (infarct-related artery-related vs. non-infarct-related artery-related; culprit lesion-related vs. non-culprit lesion-related)
|
1 year
|
|
Revascularization
Tidsramme: 1 year
|
includes ischemia-driven and non-ischemia-driven revascularization, revascularization of infarct-related and non-infarct-related arteries, revascularization of culprit and non-culprit lesions, revascularization of target vessels and non-target vessels, and revascularization of target lesions and non-target lesions
|
1 year
|
|
Stent thrombosis
Tidsramme: 1 year
|
Academic Research Consortium
|
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Junbo Ge, Doctor, Fudan University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Infarkt
- Nekrose
- Myokardiskemi
- Hjerteinfarkt
- Iskemi
- Patologiske tilstander, tegn og symptomer
- ST Elevation Hjerteinfarkt
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Minimalt invasive kirurgiske inngrep
- Diagnostisk avbildning
- Ultrasonography
- Intervensjonell ultralyd
Andre studie-ID-numre
- B2025-555
- ChiCTR2600124260 (Annen identifikator: Chinese Clinical Trail Registry)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .